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ABSTRACT 
 
Background and aims. The add-on EndoRings has been claimed to improve adenoma detection at 
colonoscopy, but available data are inconsistent. When testing a new technology, parallel and 
crossover methodologies measure different outcomes, leaving uncertainty on their correspondence. 
Aims of this study were to compare the diagnostic yield and miss rate of the EndoRings for 
colorectal neoplasia. 
Methods. Consecutive subjects undergoing colonoscopy after a positive fecal immunochemical test 
(FIT) within organized screening program in 7 Italian centers, were randomized between a parallel 
(EndoRings or Standard) or a crossover (EndoRings/Standard or Standard/EndoRings) 
methodology. Outcomes measures were the detection rates of (advanced) adenomas (A-)ADR in the 
parallel arms and miss rate of adenomas in the crossover arms.  
Results: Of 958 eligible subjects, 927 (317 EndoRings; 317 Standard; 142 EndoRings/Standard; 
151 Standard/Endorings) were included in the final analysis. In the parallel arms (mean ADR: 
51.3%; mean AADR: 25.4%), no difference between Standard and EndoRings was found for both 
ADR (RR, 1.10; 95% CI, 0.95-1.28) and A-ADR (RR, 1.16; 95% CI, 0.88-1.51), as well as for the 
mean number of adenomas and advanced adenomas per patient (EndoRings: 1.9±1.3 and 1.0±1.2; 
Standard 2.1±1.5 and 1.0±1.2; p=NS for both comparisons). In the crossover arms, no difference in 
miss rate for adenomas between EndoRings and Standard was found at per-polyp (RR, 1.43; 95% 
CI, 0.97-2.10), as well as at per-patient analysis (24% vs 26%; p=0.76).  
Conclusions: No statistically significant difference in diagnostic yield and miss rate between 
EndoRings and Standard colonoscopy was detected in FIT+ patients. A clinically relevant 
correspondence between miss and detection rates was shown, supporting a cause-effect relationship. 
 
 
INTRODUCTION 
Improvement in adenoma detection rate (ADR) at screening colonoscopy has been 
associated with an additional long-term CRC prevention rate,1 and this appears to be relevant in a 
population-based organized setting.2,3  
Two different study designs are used to evaluate whether technological improvements 
increase adenoma detection. These are the randomized parallel design and the crossover 
randomized methodology, the latter also known as tandem or back-to-back study.4 In the former, 
patients are randomized to undergo either the active intervention or the procedure but not both. In 
the crossover design patient undergoes both of the procedures in a randomized order. The main 
difference between the designs is the outcome measured, consisting of the additional diagnostic 
yield at per-patient (ADR) or per-polyp (adenomas per colonoscopy) analysis in the parallel design 
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and the decrease in the per-polyp miss rate in the tandem design. On one side, the parallel 
comparison favorably mimics the real clinical setting, but, on the other, it is hampered by the need 
of a much larger sample size and a higher risk of bias related to variability in underlying disease-
prevalence, and provides less opportunity to explain the potential superiority of the new technique.4 
The crossover design mitigates all such limitations, but it represents a fully artificial design, and it is 
also at high risk of operator bias, as the unblinded endoscopist performing the first procedure is 
aware of the subsequent colonoscopy to be performed.4 When validating the same innovations with 
different study methodologies, inconsistent results have been frequently reported,5-9 generating 
uncertainty as to how well the 2 study designs actually correspond. 
The add-on EndoRings (EndoAid Ltd, Caesarea, Israel) was developed to improve detection 
at colonoscopy by facilitating exploration of the proximal sides of folds.  Haustral folds are 
flattened by the mechanical pressure of 2 circular layers of silicone-rubber rings. Previous studies 
with different methodologies led to different results.6,10 On one hand, a crossover randomized trial 
showed a statistically significant decrease of polyp miss rate,10 whereas, on the other, a parallel 
randomized trial failed to show any superiority in ADR.6 
Population-based organized programs based on immunochemical fecal test (FIT) represent 
an ideal setting to evaluate colonoscopy innovations. The FIT-positive population is 
homogeneously-enriched for both advanced and nonadvanced neoplasia.11 The actual miss rate of 
(advanced) adenomas in this setting is not yet known. 
The aim of this study was to test whether the 2 different trial designs lead to similar results 
and conclusions by randomizing consecutive patients into an overall trial that employed both 
designs simultaneously.  The active intervention tested was EndoRings and the study population 
was FIT positive subjects. 
 
METHODS 
This randomized controlled study was conducted in 7 endoscopy centers in Northern and 
Central Italy participating in the organized CRC screening program. The protocol was approved by 
the Ethics Committee of the coordinating center (ASL RM1, Rome) and afterwards by all other 
participating institutions. Written and informed consent was obtained from all subjects enrolled in 
the study. The trial was registered on the ISRCTN data-base (ISRCTN: 56854419). All the authors 
had access to the study data and had reviewed and approved the final manuscript.  
 
CRC organized screening program in Italy 
Main features of the organized CRC screening program in Italy has already been detailed.7 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The target population is represented by 50 to 75 years eligible subjects who are invited for a 
biannual single sample FIT. Those with a positive result (cut-off=20 µg Hb/gr. feces) are invite to 
perform post-FIT+ colonoscopy.  
 
Study population 
Patients undergoing their first colonoscopy after a positive FIT were enrolled. We excluded 
from the study: (1) patients with previous colonic resection; (2) patients on anti-thrombotic therapy, 
precluding polyp resection; (3) patients who were not able or refuse to give informed written 
consent. 
 
Randomization 
FIT+-subjects were randomized in a 2:2:1:1 ratio within screening center and endoscopist to 
undergo colonoscopy with or without the EndoRings in a parallel or crossover design, based on a 
computer generated randomized blocks sequence, in 4 different arms: 
  
1. Parallel arm: colonoscopy without EndoRings (ie, Standard colonoscopy, S) 
2. Parallel arm: colonoscopy with EndoRings (E)  
 
3. Crossover arm: colonoscopy with EndoRings (first) followed by Standard 
colonoscopy without EndoRings (second), E/S 
4. Crossover arm: Standard colonoscopy without EndoRings (first) followed by 
colonoscopy with EndoRings (second) (S/E) 
 
Randomization was stratified by gender, age (50-59, 60-75 years) and screening history 
(first versus subsequent round), as already detailed.7  
 
Examination procedure 
Experienced endoscopists each having performed >5000 standard colonoscopies and >5 
EndoRings colonoscopies with unselected indication within the previous 6 months participated in 
the study. To minimize operator-related variability, only 2 endoscopists per center were included. 
For study procedures, each center was allowed to use the same scope that would have been used in 
daily clinical practice (Appendix 1), irrespective of the definition (standard vs high-definition), 
whereas the same scope`s models with the addition of EndoRings was used in the EndoRings arm. 
No chromo-endoscopy or light-modification technologies for polyp detection were allowed. Split-
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based bowel preparation was performed according to the standardized protocol used in each study 
center with at least one day of low-fiber diet before the procedure. In the crossover arms, the same 
endoscopist performed both of the consecutive procedures in the same day. If either of the 2 was 
incomplete, the patient was excluded from the primary analysis. 
 
Bowel preparation was evaluated and graded according to the Boston Bowel Preparation 
scale.12 The endoscopist and facility staff used their standard procedures for subject management 
and monitoring, including use of conscious sedation according to endoscopist’s and patient’s 
preferences.  
 
The success of cecal intubation was assessed by the endoscopist by the identification of the 
ileocecal valve and the appendix orifice via photo documentation. When the EndoRings was 
responsible for cecal intubation failure, the endoscopist was allowed to repeat the procedure without 
the EndoRings.  The result of such repetition was considered in the primary analysis only for the 
parallel arms (in order to preserve an intention-to-treat approach). On the other hand, in the 
crossover arms, failure of cecal intubation in the first procedure did not prevent the second 
procedure, if considered appropriate by the investigator, but it was excluded from the primary 
analysis. 
 
Polyps were classified according to their size, location, and morphology (pedunculated, 
sessile, and non-polypoid).13 Location was considered proximal if proximal to the splenic flexure. 
Pathologist’s measure, when available, was considered the reference standard, whereas 
endoscopist’s measure was used in the remaining cases (ie, piecemeal resection). In the 2 crossover 
arms, all lesions detected in the first examination were resected at the time of observation. The 
second procedure was performed similarly.  
 
-Assessing the duration of the examination 
Intubation time was defined as the duration of the time from the entry of the colonoscope 
into the anal verge to the time when the colonoscope arrived in the cecum, as determined by the 
investigator. Withdrawal time was defined as the duration time between cecal intubation and the 
time when the colonoscope was withdrawn from the anus. Intubation time and all other times were 
measured using a stopwatch, pausing during therapeutic interventions and washing. Clean 
withdrawal time was targeted to a minimum of 6 minutes.  
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Histopathology 
All resected lesions, either by forceps or snare, were sent to pathology in separate jars and 
were processed and stained for histopathology using standard methods and evaluated by expert 
pathologists (one in each center) according to the Vienna criteria.7, 14 An advanced adenoma was 
defined as an adenoma >10 mm and/or with villous component > 20%, and/or high-grade dysplasia.   
 
Sample size and statistical analysis 
Based on the observed prevalence of adenomas (40%), advanced adenomas (25%), 
adenomas (33%) and flat lesions (4%) among FIT+-patients, an overall sample size of 900 patients 
divided between the parallel (600 patients; 300 per each of the 2 arms) and the crossover (300 
patients; 150 per each arm) methodology could allow for a 80% power to detect as statistical 
significant (α=0.05; 2-sided test) a 11.5%, 10.5% and 6% absolute increase in the detection rate of 
adenomas, advanced adenomas and flat lesions respectively when comparing colonoscopy with and 
without EndoRings arms (parallel arms). In the crossover colonoscopy a 14% absolute difference in 
the miss rate with standard as compared to EndoRings examination could be detected as statistically 
significant, assuming a 15% miss rate with EndoRings (per-patient analysis). Also, in the per-polyp 
analysis (advanced) adenoma miss rate was defined as the number of (advanced) adenomas detected 
in the second procedure/total number of (advanced) adenomas detected in the first and second 
procedures, both at per-polyp and per-patient analysis. Assuming a 45% ADR at the first 
examination, with an average number of 2 adenomas, the planned sample size could allow to detect 
as statistically significant a 10% absolute difference (from 15% to 25%) in the proportion of 
adenomas detected at the second procedure over the total number of adenomas detected at the 2 
procedures.  
The expected increase in the ADR in the EndoRings arm is consistent with the initial data 
from previous studies comparing colonoscopy with and without EndoRings in primary screening 
setting.10 Chi-square test and t-test were used for categorical and continuous variables in the 
univariate analysis. Based on available evidence, we can assume that the ADR can be related not 
only to a set of individual characteristics, but also to the examiner’s attributes, such as skills, 
training, volume of activity and specialty, and to the characteristics of the endoscopy unit, including 
the pathology department classifying the excised lesions. Thus, a multilevel (random-intercept) 
logistic regression analysis (3 hierarchical levels: the patient, the endoscopist and the endoscopy 
unit) was performed, selecting the observed prevalence rates of adenomas (any adenoma and 
advanced adenomas only) and advanced neoplasia (AN -advanced adenoma + CRC) as main 
outcomes, as already detailed.7 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
RESULTS 
In the study period (28 July 2016 – 21 Aug 2017), 958 eligible subjects were randomized to 
the parallel arms of colonoscopy with (E: 319) and without (S: 318) EndoRings, or to the crossover 
arms, with (ES: 160) or without (SE: 161) EndoRings, at the first of the 2 examinations, 
respectively (Figure 1). After excluding 9 (2 E; 4 ES; 1 S; 2 SE) subjects who did not attend the 
planned appointment (they had been randomized at the time of the encounter to fix the colonoscopy, 
but they did not show up thereafter), 7 (2 ES; 5 SE) who refused to have the second exam and 15 
(12 ES; 3 SE) with an incomplete procedure at the first of the 2 sequential colonoscopies in the 
crossover arms, 927 subjects were included in the analysis. Subject flow is represented in Figure 1. 
Groups were comparable (Table 1) with respect to age, gender, and screening history (1° versus 
>2°subsequent FIT rounds). 
 
Quality of the examinations was also similar across the study groups (Table 1). Cecal 
intubation in the parallel arms was achieved in 309 out of 317 (97.4%) and 311 of 317 (98.1%) 
cases with and without EndoRings, respectively, whereas it was achieved in 142 of 154 (92.2%) and 
151 of 154 (98.1%) cases at the first procedure with and without EndoRings in the crossover arms. 
Bowel preparation was considered inadequate (ie, BBPS <2 in one of 3 segments) in 55 of 927 
(5.9%) subjects with no difference across the groups. Mean insertion time and withdrawal times 
were similar across the study arms. One patient reported a minor, self-limiting adverse event (vagal 
reaction). 
 
Parallel arms  
 
-Per-patient analysis  
Overall, 324 of 634 (51.1%) and 162 of 634 (25.6%) patients had at least one adenoma and one 
advanced adenoma in the study population, whereas SSP/TSA was the most advanced lesion in 
13/634 (2.1%). The distribution of the most advanced lesion across Standard and EndoRings arms is 
shown in Table 2. The proportion of subjects with at least one adenoma (ADR) was similar between 
the Standard and EndoRings arms (53.6% vs 48.6% vs RR, 1.10; 95% CI, 0.95-1.28); the 
corresponding figures for advanced adenomas were 27.4% versus 23.7% versus (RR, 1.16; 95% CI, 
0.88-1.51). No differences according to site (proximal/distal) or dimension (<10 mm/>10 mm) for 
the most advanced lesion was detected between the 2 arms (Table 2). Distribution of SSP/TSA was 
also similar between the 2 groups (Table 2).  
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The same differences between the EndoRings and the Standard colonoscopy were maintained after 
adjusting (Table 3) for gender, age, screening history, and screening center; both ADR and AADR 
were higher among men than among women, with a trend toward an increase with age, which was 
statistically significant for AADR. The AADR, but not the ADR, was decreased among subjects 
having performed previous FIT examinations; the ADR was increased when the bowel preparation 
was rated as adequate (BBPS>2 in all segments) and in those centers where withdrawal time for 
negative TCs was longer than 6 minutes in more than half of the cases.  
 
-Per-polyp analysis  
The average number of adenomas and proximal adenomas per patient (with adenomas) was 1.9±1.3 
and 1.0±1.2 in the EndoRings and 2.1±1.5 and 1.0±1.2 in the Standard arm, respectively (p=NS for 
both comparisons); the corresponding figures for SSP/TSA were 1.6 (±1.2) and 1.6 (±1.2) for total 
SSP/TSA and 1.2 (±1.2) and 1.5 (±1.3) for proximal SSP/TSA. The proportion of non-polypoid 
lesions was 5.0% (81/510) and 18.4% (98/532) in the EndoRings and in the Standard arms 
respectively (p=0.315). 
 
Crossover arms 
 
A total of 279 completed both of the crossover procedures, 139 in the EndoRings/Standard group 
and 140 in the Standard/EndoRings group (Figure 1).  The distribution of the most advanced lesion 
across each of the 2 crossover arms for each of the 2 individual procedures according to histology 
and localization is shown in Appendix 2. No difference in ADR between each of the first 
procedures in each arm (EndoRings first: 53%; Standard first: 50%) and the corresponding parallel 
arms (see above) was detected (Table 2).  
 
-Per-polyp analysis 
Among the 304 and 291 polyps detected in the EndoRings/Standard and Standard EndoRings arms, 
respectively, 61 and 70 were missed, corresponding to a miss rate of 20% and 24% for Endorings 
and Standard colonoscopy, respectively (RR, 1.20; 95% CI, 0.89-1.62). 
 
Among the 410 and 122 detected adenomas and advanced adenomas, 212 and 63 were removed in 
the EndoRings/Standard arm, and 198 and 59 in the Standard/EndoRings arm (Table 4). The 
EndoRings appeared to miss 36 out of 212 adenomas, corresponding to a miss rate of 17.0%, 
whereas the Standard missed 48 out of 198 adenomas, corresponding to a miss rates of 24.2% (RR, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1.43; 95% CI, 0.97-2.10). For advanced adenomas, the EndoRings appeared to miss 2 out of 63 
lesions, corresponding to a miss rate of 3.2%, whereas the Standard missed 5 out of 59 advanced 
adenomas, corresponding to a miss rates of 8.5% (p=0.38). Most of missed lesions (80/84; 95.2%) 
were <10 mm adenomas with similar distribution between proximal (46/84; 54.8%) and distal 
location (Table 4). Similar miss rates for SSA/TSA were also observed (Table 4). 
 
-Per-patient analysis 
Miss rate 
At least one adenoma was missed in overall 69 out of 279 patients (Table 4), corresponding to a 
miss rate of 24.7%, without difference between the 2 techniques (miss rate EndoRings, 24% vs miss 
rate Standard, 26%; p=NS). Overall, advanced adenomas were missed in 6 out of 279 patients 
(2.2%) with no difference between the 2 techniques (Table 4). No other differences at per-patient 
analysis were detected (Table 4). 
 
False negative rate and incorrect surveillance interval 
An adenoma and advanced adenoma was detected at second examination in those without any 
(advanced) adenoma at the first examination in 16 and 1 patient, respectively, corresponding to a 
false negative rate of 5.7% and 0.4%, respectively, with no difference between the 2 techniques 
(Table 4). This would have resulted in a difference surveillance strategy in 11 out of 279 (3.9%) 
patients, corresponding to a 3-year colonoscopy for multiplicity (10 cases) or advanced adenoma (1 
case) instead of FIT repetition (Table 4). 
 
DISCUSSION 
The lack of superiority of the EndoRings in (advanced) adenoma detection rate in the 
parallel arms corresponded to the lack of inferiority of the miss rate of adenomas in the crossover 
arms, supporting a cause-effect relationship between miss and detection rates. In addition, these 
results also corresponded to similar values between the 2 techniques in the mean number of 
adenomas per patient, on one side, and the miss rate at per-patient level, on the other. 
 
Our study clearly excluded any significant utility for EndoRings in the detection of both 
non-advanced and advanced lesions, as well as for proximal and small (<10 mm) lesions in FIT+ 
subjects. Similarly, EndoRings did not reduce the miss rate for adenomas both at per-polyp and per-
patient analysis.  These findings are clinically relevant as this was the first study with the 
EndoRings designed with ADR as primary end-point. The enriched-disease FIT+ setting provided a 
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sufficient number of advanced adenomas to detect a possible increase in the detection rate of these 
lesions, which was also not achieved. From a clinical perspective, our result is in line with a recent 
4-arm parallel comparison among different technologies to improve detection of colorectal 
neoplasia in a primary colonoscopy setting, showing an equivalence in the mean number of 
adenoma per patient between EndoRings and standard colonoscopy.6 On the other hand, our study 
failed to confirm a reduced miss rate of adenomas with the EndoRings, as recently shown by a 
tandem study.10 This may be at least in part related with a much higher ADR when using standard 
colonoscopy as first pass in our study  compared with the previous study – 50% versus 28% – and 
in a much lower miss rate of adenomas – 24% versus 48.3% –  of standard colonoscopy.10  
 
This is the first crossover study performed in a purely FIT+ setting. Irrespective of the 
technical comparison, our study also allowed observation of the very clinically relevant risk of 
missed lesions, ie, advanced adenomas, in a FIT + population.  We found this miss rate to be very 
low at 3.2%, and similarly found a very low number of entirely false negative subjects (subjects 
with a missed adenoma without any other detected lesion).  These results are very reassuring given 
the potential for large differences in the recommended time interval for next colonoscopy between 
persons with advanced adenomas (colonoscopy at 3 years) versus persons without (FIT at 5-10 
years). The very low rate of clinically relevant lesions missed in our study, as well as the lack of 
benefit of EndoRings, may be the result of other recent improvements in colonoscopy including 
high-definition, improved maneuverability, and split-dose cleansing. In this regard, a recent 
crossover trial showed a substantial reduction in adenoma miss rate when skipping 2 generation of 
colonoscopy system.15 
  
From a methodology perspective, our study showed a favorable correspondence between the 
detection and miss rates in the parallel and crossover arms, respectively, and also a somewhat 
unexpected coherence across all the secondary end-points at both the per-patient and per-polyp 
level. This result is to be related with a uniform performance of the study endoscopists in the 2 
methodological arms, as clearly supported by the similar values in ADR between the 2 parallel 
arms, on one side, and the 2 crossover arms (first pass), on the other. These findings are reassuring 
with regard to validation studies on any technology innovation for improving detection, irrespective 
of which of the 2 methodologies is adopted. When considering that crossover studies, albeit 
requiring a smaller sample size, are technically more demanding and less patient-friendly, parallel 
studies should be trusted as an adequate methodology to validate new technologies. 
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The main strength of our study is represented by the double randomization between the 
study design, ie, parallel and crossover, and within each study design, by the lack of intercenter 
variability in the main study outcomes, and by the similar estimates of ADR between the parallel 
and the crossover arms. The main limitation is represented by the role of ADR as intermediate end-
point in CRC prevention, as compared with interval cancer, and by the uncertain role of miss rate in 
the degree of CRC prevention.  
 
While excluding a clinically relevant effect of the EndoRings in the FIT+ setting, our study 
supports an equivalence between parallel and crossover studies when validating new technologies 
for ADR improvement.  
 
 
Figure Legend 
 
Figure 1 – Study flowchart.  
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Table 1. Patients’ characteristics and quality of colonoscopy by intervention arm 
 
 Parallel 
EndoRing 
N=317 
Parallel 
Standard 
N=317 
Crossover 
(EndoRing 
first) 
N=142 
Crossover 
(Standard first) 
N=151 
Age (years) 
mean (SD) 
 
62.9 (7.2) 
 
61.8 (6.9) 
 
61.8 (6.6) 
 
62.3 (7.1) 
Gender 
Male                   N (%)   
Female               N (%) 
 
159 (50.2) 
158 (49.8) 
 
161 (50.8) 
156 (49.2) 
 
73 (51.4) 
69 (48.6) 
 
75 (49.7) 
76 (50.3) 
Number of previous FIT 
 None                   N (%) 
 1                          N (%) 
≥ 2                        N (%) 
 
110 (34.7) 
  96 (30.3) 
111 (35.0) 
 
111 (35.0) 
  88 (27.8) 
118 (37.2) 
 
49 (34.5) 
37 (26.1) 
56 (39.4) 
 
50 (33.1) 
44 (29.1) 
57 (37.8) 
Colonoscopy competed 
No                   N (%) 
Yes                 N (%) 
 
     8  (2.6) 
 309 (97.4) 
 
    6   (1.9) 
311 (98.1) 
  12  (7.8) 
142 (92.2) 
   3   (1.9) 
151 (98.1) 
   3   (2.1) 
139 (97.9)   
 11  (7.3) 
140 (92.7) 
BBPS* 
< 6                   N (%) 
≥ 6                   N (%) 
 
16 (5.1) 
301 (94.9) 
 
21 (6.6) 
296 (93.4) 
 
5 (3.5) 
137 (96.5) 
 
13 (8.6) 
138 (91.4) 
Insertion time 
(mean+SD)** 5.5 (2.8) 5.5 (3.9) 
5.4 (2.7) 6.0 (4.0) 
3.8 (1.9) 4.6 (2.8) 
Withdrawal time 
All TCs 
(mean+SD) *** 
7.8 (3.9) 8.3 (4.8) 
7.2 (3.1) 7.8 (6.7) 
6.2 (1.8) 6.4 (4.9) 
 
*       Boston Bowel Preparation Score 
**     Information missing for: 8 pts. Group E; 9 pts. Group S; 2 pts. Group ES 1 and 8 pts Group ES 2;   
                                               2 pts. Group SE 1 and 10 pts. Group SE 2; 
*** Information missing for: 10 pts group E; 9 pts group S; 2 pts. Group ES 1 and 6 pts Group ES 2;   
                                                   3 pt. Group SE 1 and 12 pts. Group SE 2; 
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Table 2. A,  Most advanced lesion by intervention arm and colonic site. B, Statistical 
comparison across the 4 arms by using the parallel arm with standard colonoscopy (i.e. without 
EndoRings) as reference standard. 
 
 
 Parallel 
EndoRing 
 
N=317 
Parallel 
Standard 
 
N=317 
Crossover 
EndoRing first 
(1° colonoscopy) 
N=142 
Crossover 
Standard first 
(1° colonoscopy) 
N=151 
No. patients with any polyp 192 (61%) 199 (63%) 94 (66%) 92 (61%) 
No. patients with CRC 8 (3%) 12 (4%) 5 (4%) 1 (1%) 
No. patients with adenoma 154 (49%) 170 (54%) 75 (53%) 75 (50%) 
   - No. patients with  
     Non-advanced adenoma 79 (25%) 83 (26%) 40 (28%) 35 (23%) 
   - No. patients with  
     Advanced adenoma 75 (24%) 87 (27%) 35 (25%) 40 (26%) 
   - No. patients with  
     distal adenoma 93 (29%) 122 (39%) 36 (25%) 52 (34%) 
   - No. patients with   
     proximal adenoma 61 (19%) 48 (15%) 39 (27%) 23 (15%) 
 - No. patients with  
        <10 mm adenoma 93 (29%) 99 (31%) 50 (35%) 46 (30%) 
   - No. patients with  
      ≥10 mm adenoma 61 (19%) 71 (22%) 25 (18%) 29 (19%) 
No. patients with SSP/TSA 7 (2%) 6 (2%) 3 (2%) 3 (2%) 
Mean number of adenomas 
per patient with adenomas  
(mean+SD) 
1.9 (1.3) 2.1 (1.5) 2.3 (1.7) 2.0 (1.2) 
A 
     
Most advanced lesion per patient Relative Risk – 95%CI 
Any adenoma  
Standard vs EndoRing   1.10 -  0.95-1.28 
Standard vs Crossover (Standard first)  1.08 – 0.89-1.31 
Standard vs Crossover (EndoRing first)  1.02 – 0.84-1.22 
Advanced Adenoma  
Standard vs EndoRing 1.16-  0.88-1.51 
Standard vs Crossover (Standard first)  0.99 – 0.63-1.57 
Standard vs Crossover (EndoRing first)  1.11 – 0.79-1.56 
Proximal Adenoma  
Standard vs EndoRing 0.79 -  0.56-1.11 
Standard vs Crossover (Standard first)  1.04 – 0.65-1.66 
Standard vs Crossover (EndoRing first)  0.55 – 0.35-0.80 
Adenoma ≥10 mm  
Standard vs EndoRing 1.16 -  0.86-1.58 
Standard vs Crossover (Standard first)  1.17 – 0.79-1.72 
Standard vs Crossover (EndoRing first)  1.27 – 0.84-1.38 
B 
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Table 3. Factors associated with ADR at multivariable analysis (Parallel arms). 
 
 
Any adenoma Advanced adenoma 
OR* 95% CI OR* 95% CI 
Gender 
Men 
Women 
 
1 
0.65 
 
 
0.47-0.90 
 
1 
0.64 
 
 
0.44-0.92 
Age 
50-59 
60-74 
 
1 
1.39 
 
 
0.99-1.94 
 
1 
1.64 
 
 
1.11-2.42 
Number of previous FITs none 
≥1 
 
1 
0.80 
 
 
0.55-1.15 
 
1 
0.47 
 
 
0.31-0.70 
BBPS 
< 6 
≥ 6 
 
1 
5.04 
 
 
2.23-11.38 
 
1 
2.54 
 
 
0.95-6.76 
Withdrawal time (centers) 
≤ 6 minutes in ≤ 50% negative TCs   
>6 minutes in > 50% negative TCs  
 
1 
1.49 
 
 
1.03-2.15 
 
1 
1.14 
 
 
0.74-1.76 
Colonoscopy arm 
S 
E 
 
1 
0.80 
 
 
0.58-1.10 
 
1 
0.79 
 
 
0.55-1.14 
*OR = Odds ratio adjusted for all the variables in the model 
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Table 4. Miss rate at per-polyp and per-patient analysis 
 
Miss rate at per-polyp level EndoRing first Standard first P 
value 
All adenomas  (ES:212 – SE 198) 36 (17.0%) 48  (24.2%) 0.09 
Non-advanced adenomas  (ES:149 – SE 139) 34  (22.8%) 43  (30.9%) 0.15 
Advanced adenomas (ES:63 – SE 59) 2  (3.2%) 5 (8.5%) 0.38 
Distal adenomas (ES:123 – SE 104) 13 (10.6%) 25 (24.0%) 0.01 
Proximal adenomas (ES:89 – SE 94) 23  (25.8%) 23 (24.5%) 0.96 
<10 mm adenomas (ES:183 – SE 156) 36 (19.7%) 44 (28.2%) 0.08 
>10 mm adenomas (ES:29 – SE 42) 0 (0.0%) 4 (9.5%) NS 
SSA/TSA (ES:13 – SE 20) 4 (30.8%) 5 (25.0%) 0.98 
Miss rate at per-patient level  
(pts. with at least one adenoma at  
2° colonoscopy / all patients) 
N=139 
 
N=140 
 P 
value 
All adenomas  33 (24%) 36 (26%) 0.76 
Non-advanced adenomas 32 (23%) 31 (22%) 0.86 
Advanced adenomas 1 (1%) 5 (4%) 0.21 
Distal adenomas 13 (9%) 21 (15%) 0.20 
Proximal adenomas 20 (14%) 15 (11%) 0.35 
<10 mm adenomas 33 (24%) 32 (23%) 0.86 
>10 mm adenomas 0 (0%) 4 (3%) NS 
SSA/TSA 0 (0%) 3 (2%) NS 
False negative at per-patient level 
(All pts. with at least one adenoma at 2° 
colonoscopy and no adenoma at 1° 
colonoscopy / all patients)** 
EndoRing 
first 
N=139 
*** 
 Standard 
first 
N=140 
** 
 
P 
value 
All adenomas  6 (4%) 10 (7%) 0.31 
Non-advanced adenomas 6 (4%) 9 (6%) 0.43 
Advanced adenomas 0 (0%) 1 (1%) NS 
Distal adenomas 1 (1%) 4 (3%) 0.37 
Proximal adenomas  5 (4%) 6 (4%) 0.77 
<10 mm adenomas 6 (4%) 9 (6%) 0.43 
>10 mm adenomas 0 (0%) 1 (1%) NS 
SSA/TSA 0 (0%) 2 (1%) NS 
 
** Including 1 patient with LR adenoma at first TC detected with an HR adenoma at second TC: in addition 6 
patients would have received an incorrect indication for surveillance (ie, >3 adenomas after II TC) 
*** 4 patients would have received an incorrect indication for surveillance (ie, >3 adenomas after II TC) 
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Appendix 1. Colonoscopes used within this study for the standard colonoscopy arm across the 
different centers. 
 
• Olympus, CF-165/HQ180/HQ185/HQ190, PCF-H180AL series 
• Fujifilm Eluxeo 760 series 
• Pentax i10 series 
 
Appendix 2.                       Most advanced lesion by intervention arm and colonic site 
Parallel arms 
 
EndoRing Hyperplasti
c polyp 
LR 
adenoma 
< 10 mm  
SSP  
LG 
< 10 
mm 
Advanced 
adenoma  
< 10 mm 
SSP HG/ 
TSA  
< 10 mm 
LG 
Tubular 
adenoma 
≥ 10 mm 
SSP/TS
A 
≥ 10 mm 
  
HG T + 
LG/HG  
TV-V 
adenoma 
≥ 10 mm 
CRC 
Distal 
18 36 1 11 1 11 1 32 5 
5,7% 11,4% 0,3% 3,5% 0,3% 3,5% 0,3% 10,1% 1,6% 
Proximal 
13 45 2 3 1 8 0 9 3 
4,1% 14,2% 0,6% 0,9% 0,3% 2,5% 0,0% 2,8% 0,9% 
Total 
N=317 
31 81 3 14 2 19 1 41 8 
9,8% 25,6% 0,9% 4,4% 0,6% 6,0% 0,3% 12,9% 2,5% 
Standard Hyperplasti
c polyp 
LR 
adenoma 
< 10 mm  
SSP  
LG 
< 10 
mm 
Advanced 
adenoma  
< 10 mm 
SSP 
HG/TSA  
< 10 mm 
LG 
Tubular 
adenoma 
≥ 10 mm 
SSP/TS
A 
≥ 10 mm 
  
HG T + 
LG/HG  
TV-V 
adenoma 
≥ 10 mm 
CRC 
Distal 
18 59 1 10 1 17 0 36 10 
5,7% 18,6% 0,3% 3,2% 0,3% 5,4% 0,0% 11,4% 3,2% 
Proximal 
5 24 1 6 0 8 3 10 2 
1,6% 7,6% 0,3% 1,9% 0,0% 2,5% 0,9% 3,2% 0,6% 
Total 
N=317 
23 83 2 16 1 25 3 46 12 
7,3% 26,2% 0,6% 5,0% 0,3% 7,9% 0,9% 14,5% 3,8% 
 
Most advanced lesion by intervention arm and colonic site 
Crossover arms – first TC 
 
EndoRing * Hyperplastic polyp 
LR 
adenoma 
< 10 mm  
SSP  
LG 
< 10 
mm 
Advanced 
adenoma  
< 10 mm 
SSP HG/ 
TSA  
< 10 mm 
LG 
Tubular 
adenoma 
≥ 10 mm 
SSP/TSA 
≥ 10 mm 
  
HG T + 
LG/HG  
TV-V 
adenoma 
≥ 10 mm 
CRC 
Distal 
6 18 0 3 1 7 1 8 4 
4.2% 12.7% 0.0% 2.1% 0.7% 4.9% 0.7% 5.6% 2.8% 
Proximal 
5 22 1 7 0 6 0 3 1 
3.5% 15.5% 0.7% 4.9% 0.0% 4.2% 0.0% 2.1% 0.7% 
Total 
11 40 1 10 1 13 1 11 5 
21.8% 28.2% 0.7% 7.0% 0.7% 9.2% 0.7% 7.7% 5.6% 
Standard ** Hyperplastic polyp 
LR 
adenoma 
< 10 mm  
SSP  
LG 
< 10 
mm 
Advanced 
adenoma  
< 10 mm 
SSP 
HG/TSA  
< 10 mm 
LG 
Tubular 
adenoma 
≥ 10 mm 
SSP/TSA 
≥ 10 mm 
  
HG T + 
LG/HG  
TV-V 
adenoma 
≥ 10 mm 
CRC 
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Distal 
4 24 0 7 1 9 0 11 1 
2.6% 15.9% 0.0% 4.6% 0.7% 6.0% 0.0% 7.3% 0.7% 
Proximal 
7 11 1 3 0 5 1 3 0 
4.6% 7.3% 0.7% 2.0% 0.0% 3.3% 0.7% 2.0% 0.0% 
Total 
11 35 1 10 1 14 1 14 1 
7.3% 23.2% 0.7% 6.6% 0.7% 9.3% 0.7% 9.3% 0.7% 
 
Most advanced lesion by intervention arm and colonic site 
Crossover arms – second TC 
 
EndoRing  
139 completed TCs / 
142 
Hyperplasti
c polyp 
LR 
adenoma 
< 10 mm  
SSP  
LG 
< 10 
mm 
Advance
d 
adenoma  
< 10 mm 
SSP 
HG/ 
TSA  
< 10 
mm 
LG 
Tubular 
adenoma 
≥ 10 mm 
SSP/TS
A 
≥ 10 mm 
  
HG T + 
LG/HG  
TV-V 
adenoma 
≥ 10 mm 
CRC 
Distal 
4 19 0 0 0 0 0 2 0 
2.9% 13.6% 0.0% 0.0% 0.0% 0.0% 0.0% 1.4% 0.0% 
Proximal 
5 12 3 1 0 1 0 1 0 
3.6% 8.6% 2.1% 0.7% 0.0% 0.7% 0.0% 0.7% 0.0% 
Total 
9 31 3 1 0 1 0 3 0 
6.4% 22.1% 2.1% 0.7% 0.0% 0.7% 0.0% 2.1% 0.0% 
Standard  
(140 completed TCs 
/ 151) 
Hyperplasti
c polyp 
LR 
adenoma 
< 10 mm  
SSP  
LG 
< 10 
mm 
Advance
d 
adenoma  
< 10 mm 
SSP 
HG/TS
A  
< 10 
mm 
LG 
Tubular 
adenoma 
≥ 10 mm 
SSP/TS
A 
≥ 10 mm 
  
HG T + 
LG/HG  
TV-V 
adenoma 
≥ 10 mm 
CRC 
Distal 
3 12 0 1 0 0 0 0 0 
2.2% 8.6% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0% 
Proximal 
5 20 0 0 0 0 0 0 0 
3.6% 14.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Total 
8 32 0 1 0 0 0 0 0 
5.8% 23.0% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0% 
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Acronyms 
 
E: Endorings;  
S: Standard;  
CRC: colorectal cancer;  
FIT: faecal immunochemical test;  
(A-) ADR: (Advanced-) adenoma detection rate;  
SSP: sessile serrated polyp;  
DR: detection rate 
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Proof of Human Trial Registration 
 
The trial was registered on the ISRCTN data-base (ISRCTN: 56854419).  
 
https://doi.org/10.1186/ISRCTN56854419 
